Developmental Status of the Potential Vaccines for the Mitigation of the COVID-19 Pandemic and a Focus on the Effectiveness of the Pfizer-BioNTech and Moderna mRNA Vaccines.
{"title":"Developmental Status of the Potential Vaccines for the Mitigation of the COVID-19 Pandemic and a Focus on the Effectiveness of the Pfizer-BioNTech and Moderna mRNA Vaccines.","authors":"Rashed Noor","doi":"10.1007/s40588-021-00162-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose of review: </strong>Along with the continued in silico-based studies for drug designing and repurposing followed by the corresponding cell culture studies, the ongoing clinical trials with some completed regarding finding the drug efficacy and the vaccine development against the severe acute respiratory coronavirus 2 (SARS-CoV-2) have been the most functional and indispensable issue during the current COVID-19 pandemic within 2020 and onward. The present review attempted to figure out the update on this effective vaccine and discussed the other promising vaccines.</p><p><strong>Recent findings: </strong>A range of investigations on the SARS-CoV-2 genomics, on its similarities with SARS-CoV-1, and with the Middle East respiratory syndrome coronavirus (MERS-CoV) have been accomplished and the host immune dodging mechanisms by the SARS-CoV-2 have been unraveled which in turn led the scientists around the world to work rigorously on the vaccine development. Working with various vaccine platforms so far revealed the efficacy of the mRNA-1273 vaccine as the most effective one as resulted through the clinical trials which resulted in 95% positive output.</p><p><strong>Summary: </strong>Although currently commercialized mRNA-1273 vaccine appears to be effective, still several points are to be pondered regarding the sustainability of vaccine efficacy against the rising variants of SARS-CoV-2.</p>","PeriodicalId":45506,"journal":{"name":"Current Clinical Microbiology Reports","volume":"8 3","pages":"178-185"},"PeriodicalIF":3.1000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s40588-021-00162-y","citationCount":"46","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Clinical Microbiology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40588-021-00162-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/3/3 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 46
Abstract
Purpose of review: Along with the continued in silico-based studies for drug designing and repurposing followed by the corresponding cell culture studies, the ongoing clinical trials with some completed regarding finding the drug efficacy and the vaccine development against the severe acute respiratory coronavirus 2 (SARS-CoV-2) have been the most functional and indispensable issue during the current COVID-19 pandemic within 2020 and onward. The present review attempted to figure out the update on this effective vaccine and discussed the other promising vaccines.
Recent findings: A range of investigations on the SARS-CoV-2 genomics, on its similarities with SARS-CoV-1, and with the Middle East respiratory syndrome coronavirus (MERS-CoV) have been accomplished and the host immune dodging mechanisms by the SARS-CoV-2 have been unraveled which in turn led the scientists around the world to work rigorously on the vaccine development. Working with various vaccine platforms so far revealed the efficacy of the mRNA-1273 vaccine as the most effective one as resulted through the clinical trials which resulted in 95% positive output.
Summary: Although currently commercialized mRNA-1273 vaccine appears to be effective, still several points are to be pondered regarding the sustainability of vaccine efficacy against the rising variants of SARS-CoV-2.
期刊介绍：
Current Clinical Microbiology Reports commissions expert reviews from leading scientists at the forefront of research in microbiology. The journal covers this broad field by dividing it into four key main areas of study: virology, bacteriology, parasitology, and mycology. Within each of the four sections, experts from around the world address important aspects of clinical microbiology such as immunology, diagnostics, therapeutics, antibiotics and antibiotic resistance, and vaccines. Some of the world’s foremost authorities in the field of microbiology serve as section editors and editorial board members. Section editors select topics for which leading researchers are invited to contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, which are highlighted in annotated reference lists. These timely reviews of the literature examine the latest scientific discoveries and controversies as they emerge and are indispensable to both researchers and clinicians. The editorial board, composed of more than 20 internationally diverse members, reviews the annual table of contents, ensures that topics address all aspects of emerging research, and where applicable suggests topics of critical importance to various countries/regions.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
